GlassScriptPhysician profile
Omna Sharma
NPI 1043996614
$966.46
in general payments reported to CMS, 2019-2025
14 companies · $596 in 2025
The $596 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.05 · 2024: $349 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $206.36 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Pfizer INC. | $191.54 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $96.05 | 2024-2025 | Wainua, Andexxa |
| Genentech USA, INC. | $70.47 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $64.42 | 2025 | Hyqvia |
| Sk Life Science, INC. | $63.44 | 2025 | |
| Jazz Pharmaceuticals INC. | $58.65 | 2023-2024 | Epidiolex |
| Csl Behring | $46.53 | 2025 | Kcentra, Privigen |
| Tg Therapeutics, INC. | $46.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $44.81 | 2024 | |
| Abbvie INC. | $24.87 | 2025 | |
| Lundbeck LLC | $21.97 | 2025 | Vyepti |
| Averitas Pharma INC. | $17.20 | 2024 | Qutenza |
| Tanabe Pharma America, INC. | $13.67 | 2025 | Radicava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omna Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.